SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Toevoegen aan een lijst
Financiën Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.
Aandelen
2196
CNE100001M79
Farmaceutische producten
|
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 13,22 HKD | -2,36% |
|
-1,34% | -22,24% |
| 15/05 | Fosun Pharma Unit Fosun Health krijgt kapitaalinjectie van Foshan Chanxi City Investment | MT |
| 15/05 | China keurt klinische proeven voor medicijnen tegen borstkanker goed | MT |
Totale waarde
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 65.086 | 125.791 | 113.862 | 86.922 | 61.592 | 57.421 | - | - |
| Bedrijfswaarde 1 | 77.050 | 139.217 | 127.150 | 100.183 | 80.958 | 72.886 | 75.145 | 72.038 |
| K/w-verhouding | 20,5 x | 37,8 x | 26,5 x | 24,6 x | 28,1 x | 20,1 x | 15,3 x | 13,7 x |
| Dividendrendement | 1,47% | 0,8% | 1,14% | 1,19% | 1,08% | 1,57% | 2,02% | 2,54% |
| Marktkapitalisatie/omzet | 2,28 x | 4,15 x | 2,92 x | 1,98 x | 1,49 x | 1,29 x | 1,14 x | 1,07 x |
| Bedrijfswaarde/omzet | 2,7 x | 4,59 x | 3,26 x | 2,28 x | 1,96 x | 1,64 x | 1,49 x | 1,34 x |
| Bedrijfswaarde/EBITDA | 13,1 x | 22,2 x | 15,7 x | 14,5 x | 13,1 x | 10,4 x | 9,63 x | 9,75 x |
| Bedrijfswaarde/FCF | -109 x | -75 x | -137 x | -64,1 x | -42,3 x | 15,7 x | 48,9 x | 43,3 x |
| FCF Yield | -0,92% | -1,33% | -0,73% | -1,56% | -2,36% | 6,37% | 2,05% | 2,31% |
| Price to Book | 2,14 x | 3,74 x | 3,21 x | 2,11 x | 1,46 x | 1,31 x | 1,2 x | 1,16 x |
| Aantal aandelen (in duizenden) | 2.562.899 | 2.562.899 | 2.562.899 | 2.672.157 | 2.672.399 | 2.672.399 | - | - |
| Referentieprijs 2 | 26,60 | 53,99 | 48,94 | 35,24 | 25,03 | 23,81 | 23,81 | 23,81 |
| Datum van publicatie | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Miljoen2CNY
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 28.585 | 30.307 | 39.005 | 43.952 | 41.400 | 44.429 | 50.502 | 53.609 |
| EBITDA 1 | 5.874 | 6.282 | 8.105 | 6.889 | 6.160 | 6.999 | 7.802 | 7.390 |
| Bedrijfsresultaat (EBIT) 1 | 4.494 | 4.721 | 6.314 | 4.657 | 3.308 | 3.649 | 4.648 | 4.763 |
| Operationele Marge | 15,72% | 15,58% | 16,19% | 10,59% | 7,99% | 8,21% | 9,2% | 8,88% |
| Resultaat voor belastingen (EBT) 1 | 4.526 | 4.678 | 6.054 | 4.574 | 3.265 | 4.328 | 5.563 | 6.381 |
| Nettowinst (verlies) 1 | 3.322 | 3.663 | 4.735 | 3.731 | 2.386 | 3.140 | 4.124 | 4.595 |
| Nettomarge | 11,62% | 12,09% | 12,14% | 8,49% | 5,76% | 7,07% | 8,17% | 8,57% |
| WPA 2 | 1,300 | 1,430 | 1,850 | 1,430 | 0,8900 | 1,185 | 1,561 | 1,734 |
| Free Cash Flow 1 | -705,7 | -1.857 | -926,7 | -1.564 | -1.913 | 4.645 | 1.537 | 1.662 |
| FCF-marge | -2,47% | -6,13% | -2,38% | -3,56% | -4,62% | 10,46% | 3,04% | 3,1% |
| Kasstroomconversie (ebitda) | - | - | - | - | - | 66,38% | 19,7% | 22,49% |
| Kasstroomconversie (nettowinst) | - | - | - | - | - | 147,92% | 37,27% | 36,17% |
| Dividend per aandeel 2 | 0,3900 | 0,4300 | 0,5600 | 0,4200 | 0,2700 | 0,3750 | 0,4817 | 0,6039 |
| Datum van publicatie | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Miljoen2CNY
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: december | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 11.957 | 10.382 | 10.893 | 10.270 | 12.341 | 10.871 | 10.445 | 9.305 | 10.699 | 10.157 | 10.889 | 10.631 | 11.279 | 10.475 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Bedrijfsresultaat (EBIT) 1 | 1.615 | 863,1 | 1.136 | 1.046 | 1.064 | 1.427 | 1.255 | 659,6 | -34,69 | 1.021 | 363,7 | 867,5 | 456 | 706,2 | - |
| Operationele Marge | 13,5% | 8,31% | 10,43% | 10,18% | 8,62% | 13,13% | 12,02% | 7,09% | -0,32% | 10,06% | 3,34% | 8,16% | 4,04% | 6,74% | - |
| Resultaat voor belastingen (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Nettowinst (verlies) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Nettomarge | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| WPA 2 | 0,4600 | 0,1800 | 0,4200 | 0,3500 | 0,4800 | 0,3700 | 0,3000 | 0,1900 | 0,0400 | 0,2300 | 0,3050 | 0,3900 | 0,3050 | 0,1800 | 0,0500 |
| Dividend per aandeel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Datum van publicatie | 22/03/22 | 26/04/22 | 29/08/22 | 30/10/22 | 27/03/23 | 28/04/23 | 29/08/23 | 30/10/23 | 26/03/24 | 29/04/24 | - | - | - | - | - |
1CNY in Miljoen2CNY
Geschatte gegevens
Balans
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuldpositie 1 | 11.964 | 13.426 | 13.289 | 13.261 | 19.366 | 15.465 | 17.724 | 14.617 |
| Nettokaspositie 1 | - | - | - | - | - | - | - | - |
| Hefboom (schuld/ebitda) | 2,037 x | 2,137 x | 1,639 x | 1,925 x | 3,144 x | 2,21 x | 2,272 x | 1,978 x |
| Free Cash Flow 1 | -706 | -1.857 | -927 | -1.564 | -1.913 | 4.645 | 1.537 | 1.662 |
| ROE (netto-inkomsten/eigen vermogen) | 11,6% | 10,8% | 12,4% | 9,04% | 5,29% | 6,41% | 8,03% | 8,83% |
| ROA (netto-inkomsten/totale activa) | 4,53% | 4,58% | 5,35% | 3,73% | 2,18% | 2,6% | 2,9% | 3,3% |
| Totale activa 1 | 73.341 | 79.904 | 88.433 | 100.022 | 109.663 | 120.786 | 142.401 | 139.215 |
| Nettoactief per aandeel 2 | 12,40 | 14,40 | 15,30 | 16,70 | 17,10 | 18,20 | 19,80 | 20,60 |
| Cashflow per aandeel 2 | 1,260 | 1,010 | 1,540 | 1,580 | 1,280 | 2,700 | 1,760 | 2,000 |
| Capex 1 | 3.928 | 4.437 | 4.875 | 5.782 | 5.328 | 5.632 | 3.919 | 4.577 |
| Capex/omzet | 13,74% | 14,64% | 12,5% | 13,15% | 12,87% | 12,68% | 7,76% | 8,54% |
| Datum van publicatie | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Miljoen2CNY
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
Verkoop
Koop
Gemiddeld advies
Accumuleren
Aantal analisten
8
Laatste slotkoers
23,81
CNY
Gemiddelde koersdoel
28,61
CNY
Spread / Gemiddelde doel
+20,15%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +34,35% | 693 mld. | |
| +29,39% | 584 mld. | |
| -3,49% | 372 mld. | |
| +20,15% | 332 mld. | |
| +6,19% | 294 mld. | |
| +14,11% | 239 mld. | |
| -3,03% | 211 mld. | |
| +10,02% | 210 mld. | |
| +9,21% | 168 mld. |
- Beurs
- Aandelen
- Koers 600196
- Koers 2196
- Financiën Shanghai Fosun Pharmaceutical (Group) Co., Ltd.